Edition:
India

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

576.45INR
15 Dec 2017
Change (% chg)

Rs-14.00 (-2.37%)
Prev Close
Rs590.45
Open
Rs597.00
Day's High
Rs597.00
Day's Low
Rs573.20
Volume
4,312,419
Avg. Vol
1,495,482
52-wk High
Rs663.40
52-wk Low
Rs480.20

Chart for

About

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered... (more)

Overall

Beta: 0.47
Market Cap(Mil.): Rs471,067.19
Shares Outstanding(Mil.): 804.69
Dividend: 2.00
Yield (%): 0.34

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Cipla Launches Q-Tib Globally

* SAYS GOT APPROVAL FOR PRODUCT Q-TIB FROM WORLD HEALTH ORGANISATION

30 Nov 2017

BRIEF-Cipla gets final approval for generic Dacogen​

* Drug indicated for treatment of patients with myelodysplastic syndromes

20 Nov 2017

Yes Bank, IndusInd to join India's BSE Sensex index; Lupin, Cipla dropped

Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday.

17 Nov 2017

Yes Bank, IndusInd to join India's BSE Sensex index; Lupin, Cipla dropped

Nov 17 Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday.

17 Nov 2017

BRIEF-Cipla gets final approval for generic Pulmicort Respules

* Cipla receives final approval for generic Pulmicort Respules

17 Nov 2017

Morning News Call - India, November 8

To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_11082017.pdf If you would like to receive this newsletter via email, please register at: https://forms.thomsonreuters.com/india-morning/ FACTORS TO WATCH 10:00 am: Transport Minister Nitin Gadkari to brief media in Mumbai. 10:00 am: GlaxoSmithKline Consumer Healthcare post-earnings analyst conference call in Gurugram. 10:45 am: Labour Ministe

08 Nov 2017

Cipla second-quarter profit up 19 percent on higher domestic sales

Cipla Ltd, India's second largest drugmaker by market capitalisation, posted its second straight rise in quarterly profit, slightly above analysts' estimate, boosted by strong domestic sales.

07 Nov 2017

UPDATE 1-India's Cipla Q2 profit up 19 pct on higher domestic sales

Nov 7 Cipla Ltd, India's second largest drugmaker by market capitalisation, posted its second straight rise in quarterly profit, slightly above analysts' estimate, boosted by strong domestic sales.

07 Nov 2017

India's Cipla Q2 profit rises 19 pct

Nov 7 Cipla Ltd, India's second largest drugmaker by market capitalisation, posted a 19 percent rise in quarterly profit, slightly above analysts' estimate.

07 Nov 2017

BRIEF-India's Cipla Sept qtr consol profit up about 19 pct

* Sept quarter consol net profit 4.23 billion rupees versus profit of 3.54 billion rupees last year

07 Nov 2017

Earnings vs. Estimates